OBJECTIVE: The purpose of this study is to evaluate the relationship between plasma high-sensitivity C-reactive protein (hs-CRP), atrial natriuretic peptides (ANP), N-terminal-pro-brain natriuretic peptide (NT-proBNP) levels, and the risk and recurrence of atrial fibrillation (AF) after pulmonary vein isolation (PVI) in patients with paroxysmal atrial fibrillation (PAF). METHODS: Plasma ANP, NT-proBNP, and hs-CRP levels were measured before and 3 months after PVI in 33 patients with PAF and 30 control participants. RESULTS: (1) NT-proBNP levels at baseline were significantly elevated in subjects with PAF compared with control subjects (296.8 ± 272.1 vs. 80.8 ± 69.1 pg/ml), but ANP and hs-CRP levels were normal; NT-proBNP levels normalized 3 months after PVI, but ANP and hs-CRP levels did not change significantly; NT-proBNP levels at baseline in the recurrent group were markedly higher than those in the nonrecurrent AF group (572.7 ± 234.2 vs. 176.8 ± 188.7 pg/ml). (2) Cox stepwise multivariate analysis demonstrated that only elevated NT-proBNP level at baseline was an independent predictor of AF recurrence (p < 0.001) after PVI among 13 variables, such as echocardiographic parameters, plasma ANP, NT-proBNP, and hs-CRP levels. A cutoff value of NT-proBNP ≥ 423.2 pg/ml was a significant risk factor for AF recurrence (p = 0.002). CONCLUSIONS: Elevated NT-proBNP level at baseline, but not ANP and hs-CRP, is a sensitive biomarker for early predicting AF recurrence in patients with PAF.
OBJECTIVE: The purpose of this study is to evaluate the relationship between plasma high-sensitivity C-reactive protein (hs-CRP), atrial natriuretic peptides (ANP), N-terminal-pro-brain natriuretic peptide (NT-proBNP) levels, and the risk and recurrence of atrial fibrillation (AF) after pulmonary vein isolation (PVI) in patients with paroxysmal atrial fibrillation (PAF). METHODS: Plasma ANP, NT-proBNP, and hs-CRP levels were measured before and 3 months after PVI in 33 patients with PAF and 30 control participants. RESULTS: (1) NT-proBNP levels at baseline were significantly elevated in subjects with PAF compared with control subjects (296.8 ± 272.1 vs. 80.8 ± 69.1 pg/ml), but ANP and hs-CRP levels were normal; NT-proBNP levels normalized 3 months after PVI, but ANP and hs-CRP levels did not change significantly; NT-proBNP levels at baseline in the recurrent group were markedly higher than those in the nonrecurrent AF group (572.7 ± 234.2 vs. 176.8 ± 188.7 pg/ml). (2) Cox stepwise multivariate analysis demonstrated that only elevated NT-proBNP level at baseline was an independent predictor of AF recurrence (p < 0.001) after PVI among 13 variables, such as echocardiographic parameters, plasma ANP, NT-proBNP, and hs-CRP levels. A cutoff value of NT-proBNP ≥ 423.2 pg/ml was a significant risk factor for AF recurrence (p = 0.002). CONCLUSIONS: Elevated NT-proBNP level at baseline, but not ANP and hs-CRP, is a sensitive biomarker for early predicting AF recurrence in patients with PAF.
Authors: Hakan Oral; Carlo Pappone; Aman Chugh; Eric Good; Frank Bogun; Frank Pelosi; Eric R Bates; Michael H Lehmann; Gabriele Vicedomini; Giuseppe Augello; Eustachio Agricola; Simone Sala; Vincenzo Santinelli; Fred Morady Journal: N Engl J Med Date: 2006-03-02 Impact factor: 91.245
Authors: Oussama M Wazni; Nassir F Marrouche; David O Martin; Atul Verma; Mandeep Bhargava; Walid Saliba; Dianna Bash; Robert Schweikert; Johannes Brachmann; Jens Gunther; Klaus Gutleben; Ennio Pisano; Dominico Potenza; Raffaele Fanelli; Antonio Raviele; Sakis Themistoclakis; Antonio Rossillo; Aldo Bonso; Andrea Natale Journal: JAMA Date: 2005-06-01 Impact factor: 56.272
Authors: Stavroula N Psychari; Thomas S Apostolou; Loukas Sinos; Eftihia Hamodraka; George Liakos; Dimitrios Th Kremastinos Journal: Am J Cardiol Date: 2005-03-15 Impact factor: 2.778
Authors: Konstantinos P Letsas; Reinhold Weber; Gerd Bürkle; Constantinos C Mihas; Jan Minners; Dietrich Kalusche; Thomas Arentz Journal: Europace Date: 2008-11-13 Impact factor: 5.214
Authors: I Rizos; A G Rigopoulos; A S Kalogeropoulos; S Tsiodras; S Dragomanovits; E A Sakadakis; E Faviou; D T Kremastinos Journal: J Hum Hypertens Date: 2010-01-14 Impact factor: 3.012
Authors: Eleftherios M Kallergis; Emmanuel G Manios; Emmanuel M Kanoupakis; Hercules E Mavrakis; Christos A Goudis; Niki E Maliaraki; Ilias G Saloustros; Maria E Milathianaki; Gregory I Chlouverakis; Panos E Vardas Journal: Am J Cardiol Date: 2010-01-01 Impact factor: 2.778
Authors: Nisha Bansal; Leila R Zelnick; Elsayed Z Soliman; Amanda Anderson; Robert Christenson; Christopher DeFilippi; Rajat Deo; Harold I Feldman; Jiang He; Bonnie Ky; John Kusek; James Lash; Stephen Seliger; Tariq Shafi; Myles Wolf; Alan S Go; Michael G Shlipak Journal: Am J Kidney Dis Date: 2020-12-09 Impact factor: 11.072
Authors: Pascal B Meyre; Christian Sticherling; Florian Spies; Stefanie Aeschbacher; Steffen Blum; Gian Voellmin; Antonio Madaffari; David Conen; Stefan Osswald; Michael Kühne; Sven Knecht Journal: BMC Cardiovasc Disord Date: 2020-09-29 Impact factor: 2.298